The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.

@article{Mattie2016TheDA,
  title={The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.},
  author={Michael D Mattie and Arthur Raitano and Kendall Morrison and Karen Morrison and Z. G. An and Linnette Capo and Alla Verlinsky and Monica Leavitt and Jimmy Ou and Rossana Nadell and Hector Avi{\~n}a and Claudia I. Guevara and Faisal Malik and Ruth F Moser and Steven Duniho and Jeffrey Coleman and Ying Wei Li and Daniel de Souza Pereira and Fernando Do{\~n}ate and Ingrid B. J .K. Joseph and Pia M. Challita-Eid and Dennis R. Benjamin and David R. Stover},
  journal={Molecular cancer therapeutics},
  year={2016},
  volume={15 11},
  pages={2679-2687}
}
Here, we report the development of an antibody-drug conjugate, ASG-5ME, which targets the solute carrier receptor SLC44A4. SLC44A4 is a member of a family of putative choline transporters that we show to be markedly upregulated in a variety of epithelial tumors, most notably prostate and pancreatic cancer. SLC44A4 is normally expressed on the apical surface of secretory epithelial cells, but in cancer we show expression is not restricted to the luminal surface in advanced and undifferentiated… CONTINUE READING

Similar Papers

Loading similar papers…